SG11201903008YA - Hla-restricted vgll1 peptides and use thereof - Google Patents

Hla-restricted vgll1 peptides and use thereof

Info

Publication number
SG11201903008YA
SG11201903008YA SG11201903008YA SG11201903008YA SG11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA
Authority
SG
Singapore
Prior art keywords
international
vgll1
houston
apt
pct
Prior art date
Application number
SG11201903008YA
Inventor
Gregory Lizee
Cassian Yee
Janos Roszik
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11201903008YA publication Critical patent/SG11201903008YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111 1E1111111101100 1H1111011111111011111011110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/067869 Al 12 April 2018 (12.04.2018) WIP0 1 PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, A61K 38/00 (2006.01) C07K 7/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61K 39/00 (2006.01) C07K 14/00 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/US2017/055414 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 05 October 2017 (05.10.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/405,779 07 October 2016 (07.10.2016) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: BOARD OF REGENTS, THE UNIVERSI- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Austin, TX 78701 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: LIZEE, Gregory; 9000 Almeda Rd., Apt. 3301, KM, ML, MR, NE, SN, TD, TG). Houston, TX 77054 (US). YEE, Cassian; 8181 Fannin St., _ Apt. 1332, Houston, TX 77054 (US). ROSZIK, Janos; Published: 2475 Underwood St., Apt. 261, Houston, TX 77030 (US). — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) = —_ (74) Agent: MANN, Monica; Parker Highlander PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, = TX 78746 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, = (54) Title: HLA-RESTRICTED VGLL1 PEPTIDES AND USE THEREOF = = (57) : Provided herein are tumor-antigen VGLL1 specific pep- tides. Also provided herein are methods of generating VGLL1-specific = Mtl IWL Wall PEPTIDE T cells and their use for the treatment of cancer. In addition, the VGLL1- SAIELTILVPIACY A specific peptides may be used as a vaccine. = = = Emu, vow PEPI1M LOIRIETPOICT = = = SYYTMEtK is0 LAISLETPGICY bFA r_ 11 C:7 GO IN 0 --.... saw sr ,. tlIMOIRM1911116111111111 11 CZ ei FlIG. IA O
SG11201903008YA 2016-10-07 2017-10-05 Hla-restricted vgll1 peptides and use thereof SG11201903008YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662405779P 2016-10-07 2016-10-07
PCT/US2017/055414 WO2018067869A1 (en) 2016-10-07 2017-10-05 Hla-restricted vgll1 peptides and use thereof

Publications (1)

Publication Number Publication Date
SG11201903008YA true SG11201903008YA (en) 2019-05-30

Family

ID=61831506

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903008YA SG11201903008YA (en) 2016-10-07 2017-10-05 Hla-restricted vgll1 peptides and use thereof

Country Status (10)

Country Link
US (1) US11684657B2 (en)
EP (1) EP3522909A4 (en)
JP (1) JP2020503840A (en)
KR (1) KR20190057130A (en)
CN (1) CN110352067A (en)
AU (1) AU2017338911B2 (en)
CA (1) CA3039541A1 (en)
IL (1) IL265834B2 (en)
SG (1) SG11201903008YA (en)
WO (1) WO2018067869A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637028A (en) * 2016-12-29 2019-12-31 得克萨斯州大学系统董事会 HLA-restricted VCX/Y peptides and T cell receptors and uses thereof
AU2018226566A1 (en) 2017-03-03 2019-08-01 Treos Bio Limited Population-based immunogenic peptide identification platform
DE102018112644B4 (en) * 2018-05-25 2020-06-10 Epiontis Gmbh CXCR3 as an epigenetic marker for the identification of inflammatory immune cells, in particular CD8 + memory T cells
CN113329761A (en) 2018-09-04 2021-08-31 特雷斯生物有限公司 Peptide vaccine
CN115298203A (en) * 2020-03-27 2022-11-04 万可真株式会社 Compositions comprising VGLL1 peptides for the treatment of cancer
JP2023526416A (en) * 2020-05-21 2023-06-21 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム T cell receptor with VGLL1 specificity and methods of use thereof
KR20220142954A (en) * 2021-04-15 2022-10-24 한국생명공학연구원 Cell Penetrating Peptide, Anticancer peptide and Pharmaceutical Composition for Preventing or Treating Cancer comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
TWI469791B (en) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1 peptides and vaccines containing the same
US9303079B2 (en) * 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (en) * 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of proteins associated with human disease
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found Target peptides for immunotherapy and diagnostics
KR101714649B1 (en) * 2013-10-30 2017-03-10 한국생명공학연구원 Use of VGLL1 as a target for the treatment of cancer or inhibition of metatasis

Also Published As

Publication number Publication date
IL265834B2 (en) 2023-03-01
AU2017338911A1 (en) 2019-05-02
CA3039541A1 (en) 2018-04-12
KR20190057130A (en) 2019-05-27
WO2018067869A1 (en) 2018-04-12
EP3522909A4 (en) 2020-07-08
IL265834B (en) 2022-11-01
CN110352067A (en) 2019-10-18
EP3522909A1 (en) 2019-08-14
IL265834A (en) 2019-06-30
US20200040079A1 (en) 2020-02-06
US11684657B2 (en) 2023-06-27
JP2020503840A (en) 2020-02-06
AU2017338911B2 (en) 2021-09-30
WO2018067869A9 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
SG11201903008YA (en) Hla-restricted vgll1 peptides and use thereof
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201808125RA (en) Methods for solid tumor treatment
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809594WA (en) Nicotine particles and compositions
SG11201900085TA (en) Modified ligand-gated ion channels and methods of use
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201901925RA (en) Methods of treating acute kidney injury
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201908998XA (en) Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
SG11201900329XA (en) Combination test for colorectal cancer
SG11201805141QA (en) Compositions and methods for detecting and treating gastric cancer
SG11201807478QA (en) Methods and compositions for increased double stranded rna production
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies